Akebia Therapeutics Inc (NASDAQ:AKBA) has a beta value of 0.86 and has seen 0.81 million shares traded in the recent trading session. The AKBA stock price is -51.31% off its 52-week high price of $2.89 and 58.12% above the 52-week low of $0.80. If we look at the company’s 10-day average daily trading volume, we find that it stood at 7.61 million shares traded. The 3-month trading volume is 3.46 million shares.
The consensus among analysts is that Akebia Therapeutics Inc (AKBA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
Akebia Therapeutics Inc (NASDAQ:AKBA) trade information
Sporting 0.26% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the AKBA stock price touched $1.91 or saw a rise of 5.91%. Year-to-date, Akebia Therapeutics Inc shares have moved 0.79%, while the 5-day performance has seen it change -6.13%. Over the past 30 days, the shares of Akebia Therapeutics Inc (NASDAQ:AKBA) have changed 3.51%. Short interest in the company has seen 16.57 million shares shorted with days to cover at 5.03.
Wall Street analysts have a consensus price target for the stock at $6.5, which means that the shares’ value could jump 70.62% from the levels at last check today.. The projected low price target is $6.0 while the price target rests at a high of $7.0. In that case, then, we find that the latest price level in today’s session is -266.49% off the targeted high while a plunge would see the stock gain -214.14% from the levels at last check today..
Akebia Therapeutics Inc (AKBA) estimates and forecasts
The company’s shares have gained 43.98% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 32.58% over the past 5 years.
AKBA Dividends
Akebia Therapeutics Inc is expected to release its next earnings report on 2025-Mar-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders
Insiders own 4.21% of the company shares, while shares held by institutions stand at 27.33% with a share float percentage of 28.53%. Investors are also buoyed by the number of investors in a company, with Akebia Therapeutics Inc having a total of 154.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 11.64 million shares worth more than $11.87 million. As of 2024-06-30, BLACKROCK INC. held 5.5499% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 9.28 million shares as of 2024-06-30. The firm’s total holdings are worth over $9.46 million and represent 4.526% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.52% shares in the company for having 5.95 shares of worth $11.33 million while later fund manager owns 5.43 shares of worth $10.35 million as of Feb 28, 2025 , which makes it owner of about 2.30% of company’s outstanding stock.
